182. Cancer Discov. 2018 Apr;8(4):377-378. doi: 10.1158/2159-8290.CD-NB2018-015. Epub 2018 Feb 16.Arvinas, Pfizer Team Up on PROTACs.[No authors listed]Biotechnology startup Arvinas is developing proteolysis-targeting chimeras(PROTAC) that combat cancer by degrading disease-causing proteins. The company's first PROTACs will target prostate and breast cancers, and a recent deal withPfizer will allow Arvinas to develop PROTACs for other cancer types.Â©2018 American Association for Cancer Research.DOI: 10.1158/2159-8290.CD-NB2018-015 PMID: 29453240 